Compare GOTU & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOTU | AVIR |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | China | United States |
| Employees | N/A | 55 |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.8M | 399.3M |
| IPO Year | 2019 | 2020 |
| Metric | GOTU | AVIR |
|---|---|---|
| Price | $1.85 | $4.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 557.6K | 356.0K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | $17.33 | N/A |
| Revenue Next Year | $13.02 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $2.78 |
| 52 Week High | $4.12 | $6.45 |
| Indicator | GOTU | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 60.71 | 60.55 |
| Support Level | $1.65 | $4.14 |
| Resistance Level | $2.01 | $5.04 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 88.93 | 83.67 |
Gaotu Techedu Inc is a technology-driven education company that provides online live courses in a large-class setting backed by its proprietary technology infrastructure. The company offers courses in large-class format, which amplifies the benefits of online education and allows it to rapidly expand its student base. It operates solely in the PRC and all assets are located in the PRC. The learning services that the company offers include Traditional Learning Services, Non-Academic Tutoring Services, and College Student and Adult Education Services. It derives maximum revenue from Learning Services and also from Educational content & digitalized learning products.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.